May 24, 2021

Emerald Health Pharmaceuticals Expands Scientific Advisory Board with the Appointment of Neuroscience Expert Dr. Eduardo Candelario-Jalil

Angelita Garcia2021-05-24T11:13:53-07:00May 24, 2021|

May 4, 2021

Emerald Health Pharmaceuticals Company Update: March 2021

Angelita Garcia2021-05-04T16:29:16-07:00May 4, 2021|

May 4, 2021

Form 1-K

Angelita Garcia2021-05-04T16:17:05-07:00May 4, 2021|

Apr 6, 2021

Form 1-U

Angelita Garcia2021-04-06T21:40:21-07:00Apr 6, 2021|

Mar 16, 2021

Multiple Sclerosis & EHP’s Unique Promising Therapeutic Approach

Angelita Garcia2021-03-17T15:03:02-07:00Mar 16, 2021|

Mar 9, 2021

Emerald Health Pharmaceuticals Announces Final Closing Date For its Regulation A+ Offering

Angelita Garcia2021-03-10T13:24:25-08:00Mar 9, 2021|

Mar 9, 2021

Form 1-U

Angelita Garcia2021-03-09T11:38:21-08:00Mar 9, 2021|

Mar 8, 2021

Emerald Health Pharmaceuticals Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis

Angelita Garcia2021-03-08T11:00:05-08:00Mar 8, 2021|

Feb 9, 2021

Form 1-U

Angelita Garcia2021-02-25T12:48:09-08:00Feb 9, 2021|

Feb 9, 2021

Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate with Multi-Modal Mechanism of Action in Parkinson’s Disease

Angelita Garcia2021-02-09T11:36:25-08:00Feb 9, 2021|